Podcasts about marrow transplantation

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Yi Bin Chen, MD Guest: Olaf Penack, MD For the past several decades, standard treatment for acute graft-versus-host disease (aGVHD) has been systemic high-dose steroids.1 While essential in some ways to initially control aGVHD, steroids are not beneficial in the long run due to the immunosuppression and toxicities associated with high cumulative doses.1,2 So what can be done moving forward to improve first-line steroid response and minimize cumulative steroid exposure? Joining Dr Charles Turck to discuss the potential of nonimmunosuppressive steroid-sparing agents for the first-line treatment of aGVHD are Drs Yi Bin Chen and Olaf Penack. Dr Chen is the Director of the Hematopoietic Cell Transplant and Cell Therapy Program at Massachusetts General Hospital, and Dr Penack is a senior physician and principal investigator within Hematology and Oncology at Charité Berlin. References: Bell EJ, Yu J, Bhatt V, et al. Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease. Transplant and Cell Ther. 2022;28(10):707.e1-707.e7. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150-1163. © 2025 CSL BehringCMD-964-0016-JAN25

CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP, an assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington, and Shernan Holtan, MD, the chief of Blood and Marrow Transplantation and professor of Medicine at Roswell Park Comprehensive Cancer Center.  The conversation took place during the 2025 Tandem Meeting and highlighted many significant presentations and posters on CAR T-cell therapies and transplantation, Banerjee's and Holtan's respective areas of expertise. The following trials were discussed: LBA1 - Phase II Multicenter Trial of Idecabtagene Vicleucel (Ide-cel) Followed By Lenalidomide Maintenance for Multiple Myeloma Patients with Sub-Optimal Response after an Upfront Autologous Hematopoietic Cell Transplantation: Top Line Results from the BMT CTN 1902 Clinical Trial1 “This [study] is nice because it merges 2 worlds. It's like a tandem—but not really a tandem—because you're not doing 2 transplants back-to-back. You're doing a transplant followed by CAR T-cell therapy,” said Banerjee. Abstract 50 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium2 “In a relatively small cohort, [investigators] found no difference in 9-month survival whether someone got their [CAR T cells] in second-line therapy vs third-line therapy from a statistical perspective. If you look at the curves, it looks like there is a potential benefit to second-line therapy, but there was not enough statistical power to determine a difference,” said Holtan. Poster 340 - CD83 Expression By Human Breast Cancer Mediates Effective Killing By CAR T3 “If there's a way to do [the therapy] armored and have a paracrine delivered in real time—and not given to the whole body—[so] the patient [would] have all the adverse effects and cytokine release syndrome release on their own…that would be awesome,” stated Banerjee.  Poster 317 - Risk Factors for Immune Effector Cell-Associated Enterocolitis (IEC-colitis) in Patients with Relapsed Myeloma Treated with Ciltacabtagene Autoleucel (cilta-cel)4 “From the best that we can tell, ironically, corticosteroids aren't the fix that we want them to be [for immune effector cell-associated colitis]…We were like ‘Diarrhea, whatever. Let's give some steroids and treat it like gut graft-versus-host-disease,' but these patients [didn't] respond as well [to that],” said Banerjee. Poster 572 - Post-CAR-T Driving Restrictions Appear Unnecessary after Week 4: Data from the US Multiple Myeloma Immunotherapy Consortium5 “Patients and their caregivers [who have] put their life aside for 4 weeks just to get through CAR T-cell therapy and the Risk Evaluation and Mitigation Strategies requirements are now being told ‘You're free to go, but you can't drive for 4 weeks, which means you can't get your own groceries or…go to doctor's appointments by yourself.' Basically, we argue…that this [requirement] is not evidence-based,” stated Banerjee.  Presentation 58 - Physical Function Measures Identify Non-Hodgkin Lymphoma Patients at High Risk of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and 1-Year Mortality after Chimeric Antigen Receptor T (CAR-T) Cell Therapy6 “This [presentation] highlights that even within a high [CAR-HEMATOTOX group], those patients were at extraordinarily high risk of not benefitting from CAR T-cell therapy, and these tests are so simple to do. It's going to be interesting to see if others can reproduce this,” said Holtan. Poster 618 - Comparison of Outcomes after Hematopoietic STEM Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Patients Older or Younger THAN 65 YEARS Old. a Retrospective Analysis of the Latin America Registry7 “My personal hope for this space is that our field can come up with more novel conditioning regimens such that we can ablate the marrow without causing those gastrointestinal toxicities or other organ toxicities [while] doing that so effectively that we don't even need maintenance therapies for a lot of conditions,” stated Holtan. Presentation 39 - Determinants of Immune Suppression Discontinuation in the Modern Era: A CIBMTR Analysis of 18,642 Subjects8 “I'm going to make a provocative prediction for the next paper [approximately 10 years from now]. I predict that steroids won't be the first-line therapy for acute or chronic graft-versus-host-disease,” Holtan said. Poster 516 - Patient Experiences with Chronic Graft-Versus-Host Disease and Its Treatment in the United States: A Retrospective Social Media Listening Study9 “We can still work together to make life as good as we possibly can [for patients], to improve physical function, to take away some of this mental distress, and then work together for advocacy too. [We can] help with peer support, help with resources, and help relieve some of that misunderstanding in the community,” stated Holtan. References 1.        Garfall AL, Pasquini MC, Bai L, et al. Phase II multicenter trial of idecabtagene vicleucel (ide-cel) followed by lenalidomide maintenance for multiple myeloma patients with sub-optimal response after an upfront autologous hematopoietic cell transplantation: top line results from the BMT CTN 1902 clinical trial. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Abstract LBA-1. 2.        Rojek AE, Ahmed N, Gomez-Llobell M, et al. CAR T cell therapy in early relapsed/refractory large B-cell lymphoma: real world analysis from the cell therapy consortium. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Abstract 50. 3.        Betts BC, Davilla ML, Linden AM, et al. CD83 expression by human breast cancer mediates effective killing by CAR T. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 340. 4.        Chang Lim KJ, Chhabra S, Corraes ADMS, et al. Risk factors for immune effector cell-associated enterocolitis (IEC-colitis) in patients with relapsed myeloma treated with ciltacabtagene autoleucel (cilta-cel). Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 317. 5.        Banerjee R, Richards A, Khouri J, et al. Post-CAR-T driving restrictions appear unnecessary after week 4: data from the US multiple myeloma immunotherapy consortium. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 572. 6.        Herr M, McCarthy P, Jacobsen H, et al. Physical function measures identify non-Hodgkin lymphoma patients at high risk of immune effector cell-associated neurotoxicity syndrome (ICANS) and 1-year mortality after chimeric antigen receptor T (CAR-T) cell therapy. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Presentation ID 58. 7.        Duarte FB, Garcia YDO, Funke VAM, et al. Comparison of outcomes after hematopoietic STEM cell transplantation (HCT) for myelodysplastic syndrome (MDS) patients older or younger THAN 65 YEARS Old. A retrospective analysis of the Latin America registry. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 618. 8.        Pidala J, DeFlilipp Z, DeVos J, et al. Determinants of immune suppression discontinuation in the modern era: a CIBMTR analysis of 18,642 subjects. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Presentation ID 39. 9.        Cowden M, Derrien-Connors C, Holtan S, et al. Patient experiences with chronic graft-versus-host disease and its treatment in the United States: A retrospective social media listening study. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 516.

When we talk about myelin damage, most of us typically think of the brain. After all, that myelin is located in your central nervous system. But the inflammation that causes myelin damage may be triggered by activity that's taking place well south of your central nervous system, in your gut microbiome, the colony of trillions of bacteria and microorganisms that live in your intestines.  Dr. Ashutosh Mangalam joins me to help us understand what this gut-brain connection is all about, how that connection impacts MS, and what you can do to change the makeup of your gut microbiome. Dr. Mangalam is an Associate Professor of Pathology at the Carver College of Medicine at the University of Iowa, where his research is focused on studying the gut microbiome and the immune system in multiple sclerosis. We're also talking about the newly published guidance from the European Committee for Treatment and Research in MS and the European Society for Blood and Marrow Transplantation, recommending autologous hematopoietic stem cell transplantation (aHSCT) for treating some cases of relapsing-remitting MS. We'll tell you about an experimental drug that may resolve MS-related vision issues through remyelination.  And we'll introduce you to this year's winner of the Barancik Prize for Innovation in MS Research. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: The gut-brain connection (and what it means if you're liviing with MS)  :22 The European Committee for Treatment and Research in MS and the European Society for Blood and Marrow Transplantation issue a recommendation for stem cell therapy to treat relapsing-remitting MS  1:35 Researchers develop a drug that may resolve MS-related vision issues through remyelination  4:44 National MS Society names this year's winner of the Barancik Prize for Innovation in MS Research  7:23 Dr. Ashutosh Mangalam explains how (and why) the brain-gut connection impacts MS    11:14 Share this episode  35:38 Have you downloaded the free RealTalk MS app?  35:58 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/388 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com RealTalk MS on YouTube https://www.youtube.com/@RealTalkMS Autologous Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder -- Recommendations from ECTRIMS and EBMT https://www.nature.com/articles/s41582-024-01050-x National MS Society Releases Recommendations for aHSCT-Bone Marrow Transplant for MS https://nationalmssociety.org/news-and-magazine/news/national-ms-society-releases-recommendations STUDY: Incomplete Remyelination Via Therapeutically Enhanced Oligodendrogenesis Is Sufficient to Recover Visual Cortical Functionhttps://www.nature.com/articles/s41467-025-56092-6 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 388 Guest: Dr. Ashutosh Mangalam Privacy Policy

Dr. Alessi reflects on his 15th anniversary of hosting Healthy Rounds on WTIC 1080, sharing insights into the origins of the show and how it came to be. He also speaks with Dr. Kapil Meleveedu, Assistant Professor of Medicine and Director of Blood and Marrow Transplantation at UConn Health Center, about the intricacies of bone marrow transplants and the associated procedures.

BUFFALO, NY- October 11, 2024 – A new #editorial was #published in Oncotarget's Volume 15 on October 1, 2024, entitled, “Transplant or no transplant for TP53 mutated AML.” As highlighted in this editorial, TP53 mutations (mut) occur in 10–15% of acute myeloid leukemia (AML) cases, commonly associated with therapy-related AML (t-AML) and complex cytogenetics (CG). TP53-mut AML is inherently resistant to conventional chemotherapies and continues to show a poor prognosis, even with venetoclax-based therapies. Allogeneic hematopoietic stem cell transplant (allo-HCT) remains a potential curative option, though only 10–15% of patients receive it. In a recent study, allo-HCT was the only variable significantly improving survival, despite only 16% of patients successfully bridging to it. In their editorial, researchers Talha Badar, Moazzam Shahzad, Ehab Atallah, Mark R. Litzow, and Mohamed A. Kharfan-Dabaja from the Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program at Mayo Clinic (Jacksonville, Florida) evaluated the outcomes of TP53-mutated AML patients based on data from the Consortium of Myeloid Malignancies and Neoplastic Diseases (COMMAND). The study found a “dismal” survival rate of 8.5 months, with no significant difference among treatment types, and allo-HCT was the only variable associated with improved survival. The authors also report on the “better long-term outcomes” when allo-HCT was performed during Complete Remission 1 (CR1) in previous observations. They acknowledge the limitations of their retrospective analysis, including selection bias, data heterogeneity from participating institutions, and the lack of complete molecular data prior to allo-HCT that might have influenced the results. Nevertheless, the findings are encouraging and suggest that allo-HCT improves long-term outcomes in this poor prognostic disease, where effective therapies remain limited. “In summary, this study reported improved survival when allo-HTC was performed in CR1 versus after later lines of therapy.” DOI - https://doi.org/10.18632/oncotarget.28652 Correspondence to - Talha Badar - badar.talha@mayo.edu Video short - https://www.youtube.com/watch?v=OQue9gbqsxE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28652 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, AML, TP53 mutation, allogeneic stem cell transplant About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Dr. Paul Szabolcs trained at Semmelweis University School of Medicine in Budapest. He completed his residency at Bellevue Hospital/NYU Medical Center and was Chief Fellow at Sloan Kettering Cancer Center in New York City. He completed postdoctoral fellowships at Memorial Sloan Kettering in Molecular Biology and at Rockefeller University in Physiology and Cellular Immunology. He has been Chief of the Blood and Marrow Transplantation and Cellular Therapies division at the UPMC Children's Hospital of Pittsburgh since 2011. Dr. Szabolcs has dedicated his career to developing effective “reduced-intensity” chemotherapy regimens for patients in need of a blood or bone marrow transplant, especially children with rare immune-system defects and degenerative brain diseases.

In this episode of "ASTCT Talks," Dr. Shernan Holtan sits down with Dr. Samer Al-Homsi, as he shares his insights on the future of graft versus host disease (GVHD) prophylaxis, particularly in haploidentical transplantation. Dr. Al-Homsi delves into the innovative CAST regimen, which combines post-transplant cyclophosphamide, abatacept and short-duration tacrolimus. Learn about the challenges, breakthroughs and promising results that could revolutionize how we approach GVHD prevention and treatment, making a future without GVHD a reality. Listen in as we explore the potential for reducing transplant toxicities and the impact on patient care. About Dr. Samer Al-Homsi A. Samer Al-Homsi, MD, MBA, is the System Chief of Blood and Marrow Transplant and Cellular Therapy at Northwell Health Cancer Institute and serves as Director of Faculty and Academic Affairs in Medical Oncology. He is a Professor of Medicine at the Zucker School of Medicine and of Cancer Research at Feinstein Institutes of Medical Research. Previously, he was the Executive Director of Blood and Marrow Transplantation at NYU Grossman School of Medicine. Dr. Al-Homsi graduated from Damascus Medical School and trained in Hematology and Medical Oncology in France. He completed his residency at Advocate Health Care and fellowship at the University of Massachusetts. He has led programs in Malignant Hematology and Blood and Marrow Transplantation at several institutions, including NYU Langone Health. His research focuses on preventing graft-versus-host disease (GvHD), developing innovative approaches such as the CyBor and CAST regimens, particularly in haploidentical transplants. Dr. Al-Homsi aims to address healthcare disparities due to donor shortages among minority groups. Dr. Al-Homsi is also the President of the American Arab Assembly of Cellular Therapy and Transplantation (AAACTT), promoting collaboration among its members. About Dr. Shernan Holtan Dr. Holtan is a clinical/translational investigator. Her work focuses on increasing resilience, both at the tissue level to prevent and treat GVHD, and at the whole person level, designing exercise programs to mitigate cancer therapy-associated aging. In GVHD, her early work focused on epidermal growth factor and pregnancy hormones to facilitate tissue repair in GVHD, which led to a successful phase II study for the treatment of high-risk acute GVHD and discovery of the GVHD biomarker amphiregulin. More recently, she has led and published two prospective clinical trials regarding the use of PTCy as GVHD prophylaxis, the results of which are changing practice around the globe. Dr. Holtan has also been a competitive powerlifter, setting a national record in 2019. She has leveraged her knowledge regarding strength training into translational studies and clinical trials that are helping to reverse some of the damage done by high-dose chemotherapy and radiation. Through her multidimensional accomplishments, Dr. Holtan has demonstrated a unique and powerful intersection of medical research and physical resilience, redefining standards of care in HCT, and innovatively combating the deleterious effects of cancer treatment.

In this week's episode we'll discuss assessing risk profile in Wiskott-Aldrich Syndrome, or WAS. Then, we'll learn about how the loss of DNMT3A confers resistance to interferon-alpha in hematopoietic stem cells carrying the JAK2-V617F mutation. Finally, we'll explore unrelated donor selection for AML patients undergoing hematopoietic stem cell transplantation with post-transplant cyclophosphamide.Featured Articles: Wiskott-Aldrich Syndrome: A retrospective study on 577 patients defines the genotype as a predictive biomarker for disease severity and survivalLoss of Dnmt3a increased self-renewal and resistance to pegylated interferon-alpha in JAK2-V617F-positive myeloproliferative neoplasms Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Dr. Guy Handley, Assistant Professor of Medicine with the Division of Infectious Diseases, USF Morsani College of Medicine, provides an overview of Human Herpesvirus 6 in Stem Cell Transplant Patients. Dr. Handley uses clinical cases to describe several scenarios related to HHV6 infection. Topics discussed include background, HHV6 latency, reactivation, clinical presentation, encephalitis, treatment strategies, and outcomes. Guidelines for HHV care are also discussed. Dr. Handley closes by discussing controversies and future directions in HHV6 management.

When Laurie Strongin's son Henry was born with the rare, often fatal disease of Fanconi anemia, doctors told her that the best way to save his life was with an umbilical cord blood transplant from a genetically matched sibling. But Henry had no matching siblings. Laurie and her husband then got a call from a doctor with a novel idea of combining three technologies to create a child who was guaranteed to be a genetic match, raising the question: is it ethical to create a life in order to save another? Show Notes: In addition to Laurie Strongin, this episode features interviews with: John Wagner, Co-Leader of the Transplantation and Cellular Therapy Program, Professor in the Division of Transplant and Cell Therapy in the Department of Pediatrics, and the McKnight-Presidential Endowed Chair, Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota Jeffrey Kahn, Andreas C. Dracopolous Director of the Johns Hopkins Berman Institute of Bioethics You can learn more about Fanconi anemia, learn about the latest research, and find resources for those affected by the disease here. You can read more about the Strongin-Goldbergs' and the Nashes' stories in this New York Times article from 2001.  Laurie Strongin went on to found the Hope for Henry Foundation, which works with hospitals to help provide support and better care for pediatric patients. To learn more about the ethics issues raised in this episode, visit the Berman Institute's episode guide.   The Greenwall Foundation seeks to make bioethics integral to decisions in health care, policy, and research. Learn more at greenwall.org.  See omnystudio.com/listener for privacy information.

When Laurie Strongin's son Henry was born with the rare, often fatal disease of Fanconi anemia, doctors told her that the best way to save his life was with an umbilical cord blood transplant from a genetically matched sibling. But Henry had no matching siblings. Laurie and her husband then got a call from a doctor with a novel idea of combining three technologies to create a child who was guaranteed to be a genetic match, raising the question: is it ethical to create a life in order to save another? Show Notes: In addition to Laurie Strongin, this episode features interviews with: John Wagner, Co-Leader of the Transplantation and Cellular Therapy Program, Professor in the Division of Transplant and Cell Therapy in the Department of Pediatrics, and the McKnight-Presidential Endowed Chair, Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota Jeffrey Kahn, Andreas C. Dracopolous Director of the Johns Hopkins Berman Institute of Bioethics You can learn more about Fanconi anemia, learn about the latest research, and find resources for those affected by the disease here. You can read more about the Strongin-Goldbergs' and the Nashes' stories in this New York Times article from 2001.  Laurie Strongin went on to found the Hope for Henry Foundation, which works with hospitals to help provide support and better care for pediatric patients. To learn more about the ethics issues raised in this episode, visit the Berman Institute's episode guide.   The Greenwall Foundation seeks to make bioethics integral to decisions in health care, policy, and research. Learn more at greenwall.org.  See omnystudio.com/listener for privacy information.

In this latest episode of ASTCT Talks, Dr. Rebecca Gonzalez sits down with Dr. Katie Gatwood and Dr. Timothy Porter to kick off National Pharmacy Month by discussing the clinical implications of post-transplant cyclophosphamide (PTCy) use outside of the haploidentical setting. They delve into their respective cancer centers' primary donor sources for match unrelated donors and the breakdown of conditioning intensity within their hematologic patients. They delve into the future of PTCy discussing the potential for earlier de-escalation of immunosuppressants to limit drug-related toxicities and optimize patient outcomes as well as important supportive care considerations. Despite the exciting prospects, the need for robust prospective data before implementation is emphasized. About Dr. Rebecca Gonzalez Dr. Rebecca Gonzalez (@xnyerin) received her Doctor of Pharmacy degree from the University of Florida College of Pharmacy. She completed her PGY2 Oncology residency at West Virginia University in Morgantown, West Virginia. Following post-doctoral training, Dr. Gonzalez was a Hematology Clinical Pharmacist at the Roswell Park Cancer Institute prior to transitioning to Moffitt Cancer Center in 2015. She is Board Certified in Oncology Pharmacy and currently practices as a Clinical Pharmacist in Blood and Marrow Transplant/Cellular Immunotherapy at Moffitt in Tampa, Florida. She was a past chair of the ASTCT Pharmacy Program Planning Committee in 2021-2022 and has been involved in several ASTCT teaching activities since 2017. Her interests include survivorship, GVHD, supportive care and infectious disease complications related to transplant and immune cellular therapy. About Dr. Katie Gatwood Dr. Gatwood is a Board-Certified Oncology Pharmacist and Clinical Pharmacist Specialist specializing in Adult Stem Cell Transplant and Cellular Therapy at Vanderbilt University Medical Center. She holds a Doctor of Pharmacy degree from the University of Michigan and completed her residency training at the University of North Carolina Health Care. Dr. Gatwood is the chair-elect of the ASTCT Pharmacy SIG Sterring Committee. She was also awarded the 2021 ASTCT Pharmacy SIG New Practitioner Award and is passionate about clinical research and education, with a focus on VOD, CAR T-cell therapy, and oncology pharmacists' role in ambulatory care. About Dr. Timothy Porter Dr. Timothy Porter is a Board-Certified Oncology Pharmacist and practices as a Clinical Pharmacy Specialist in Blood and Marrow Transplantation and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, FL. He earned a Doctor of Pharmacy degree from Duquesne University School of Pharmacy and then completed a PGY1 Pharmacy Residency at Allegheny General Hospital in Pittsburgh, PA, followed by a PGY2 Oncology Pharmacy Residency at The Johns Hopkins Hospital in Baltimore, MD. He then practiced as a Clinical Pharmacy Specialist in Blood and Marrow Transplantation and Cellular Therapy at The Johns Hopkins Hospital before transitioning to Moffitt Cancer Center in 2022. Dr. Porter is a member of the ASTCT Pharmacy SIG Education Committee and serves as the Journal Club Lead. His professional interests include management of infectious complications in immunocompromised patients, GVHD, CAR T-cell therapy, clinical research, and education.

Welcome to Living Well with MS, where we are pleased to welcome Professor Richard Burt as our guest! Professor Burt is a leading expert in hematopoietic stem cell transplantation (HSCT) for autoimmune diseases including MS and has been awarded a number of prestigious accolades. Watch this episode on YouTube here. Keep reading for the key episode takeaways and Professor Burt's bio. Questions and Timestamps 02:35 Could you introduce yourself and tell us about your work with patients with autoimmune conditions and MS? 12:03 What do you think about the idea of flipping the model and offering the most aggressive treatment options to patients first? 16:27 What are the risks of HSCT? 21:18 Can you tell us about the costs associated with stem cell transplantation? 24:13 What type of patients respond best to HSCT? 31:16 Do you see a future where doctors are trained in multiple fields and understand the whole picture of autoimmunity? 38:10 If someone's interested in exploring HSCT, what should they look for in a clinic or physician? 41:47 HSCT has a high upfront cost but how does that compare to being on an MS drug for years or perhaps a lifetime? 53:50 The Dalai Lama wrote the introduction to your book 'Everyday Miracles'. How did that come about? Selected Key Takeaways Randomised controlled trial results for HSCT have been very positive 05:12 “In a randomised trial, [HSCT] was just hands down much better than any [other] drug. All the drugs you use for MS are based on approval for slowing disease activity. That is slowing the number of relapses or slowing the rate of progression of disability but not stopping it or not reversing it. Often you stay on these drugs indefinitely. A transplant, on the other hand, is a one-time treatment and afterwards, you get better, your neurologic disability reverses, nothing else had done that.” It's important to consider the disease trajectory, risks, and benefits of stem cell transplants. 14:02 “MS causes accelerated loss of brain volume, that is brain atrophy. Unfortunately, as we age, we get brain atrophy and a normal, very low, but normal decline. But once you get MS, that decline takes a much sharper drop, and you're losing neural function a lot faster than normal ageing. For some reason, that's not viewed as a sub-acute or semi-emergency situation that you want to reverse. Traditional drugs have mostly just slowed that rate of decline, but it's still faster than what happens with normal ageing. I would think a more aggressive approach up front would be wise, but you always have to remember [the] risk–benefit. If we could do a stem cell transplant with zero risk of mortality, I would say absolutely for everybody. But you can't do that right now.” A medical speciality and institute for autoimmunology could help push the field forward 34:20 “There are 80 different autoimmune diseases that I can think of offhand. They're all “homeless” in different departments like Crohn's disease [which is] in gastroenterology, Scleroderma [which] is in rheumatology, and multiple sclerosis [which] is in neurology. They're all separated [into] different areas. If there was a better organisation, beginning at a federal level with a national institute of autoimmune diseases that supports centres of excellence around the country, that would really help this go forward.” Want to learn more about living a full and happy life with multiple sclerosis?  Sign up to our newsletter to hear our latest tips. More info and links: Visit Professor Burt's website Read Professor Burt's new book on HSCT for autoimmune diseases ‘Everyday Miracles' Check out Professor Burt's medical textbook ‘Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases' Find out more about the StarMS trial in the UK New to Overcoming MS? Visit our introductory page  Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out:  Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us:  If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS. Professor Richard Burt's bio: Professor Richard Burt is a Fulbright Scholar, Professor of Medicine at Scripps Health Care, tenured retired Professor of Medicine at Northwestern University, and CEO of Genani Biotechnology. He endeavored for 35 years, first with animal models and then with some of the world's first clinical trials, to bring the field of stem cell and cellular therapy to the patients' bedsides. Publishing Professor Burt has published more than 145 first-author articles and is the editor of four medical textbooks. He was the first Autoimmune Committee Chairperson for the International Bone Marrow Transplant Registry (IBMTR) and was the principal investigator of a National Institutes of Health (NIH) $10 million multicenter contract to develop stem cell clinical trials for autoimmune diseases. Hematopoietic stem cell transplants Professor Burt performed America's first hematopoietic stem cell transplant (HSCT) for multiple sclerosis (MS), systemic lupus erythematosus (SLE), Crohn's disease (CD), stiff person syndrome (SPS), and chronic inflammatory demyelinating polyneuropathy (CIDP) and published the world's first randomised clinical stem cell transplantation trials for systemic sclerosis and multiple sclerosis. Awards and achievements He has been awarded the Leukemia Scholar of America, the Lupus Foundation of America Fidelitas Award, the van Bekkum Award by the European Society for Blood and Marrow Transplantation, the Distinguished Clinical Achievement Award by the Clinical Research Forum, and the European Group for Blood and Marrow Transplantation Clinical Achievement Award. Professor Burt was presented in Vatican City, Rome, with the “Keys to the Vatican,” was a speaker at the Festival of Thinkers in Leadership in Healthcare in the United Arab Emirates and chaired the biotechnology session at the Baku Azerbaijan International Humanitarian Forum. Professor Burt was recognised by Science Illustrated for accomplishing one of the top 10 medical breakthroughs for the next 10 years and by Scientific American as one of the top 50 individuals for improving humanity and outstanding leadership.

Robert Soiffer, MD, is the Chief of the Division of Hematologic Malignancies at Dana Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine at Harvard Medical School. A renowned malignant hematology researcher, Dr. Soiffer has served as President of the American Society of Blood and Marrow Transplantation and is the immediate past chair of the board of the National Marrow Donor Program. He has co-authored more than 400 peer-reviewed manuscripts, book chapters, review articles, editorials, and monographs. “Early in my career, when I would mentor people, I would explain to them exactly how I did what I did. A lot of folks would say, I want to be like you. But you need to realize that you're not like me, you're different, you're YOU. So you have to find your own path.” Known as a “mentor to mentors”, Dr. Robert Soiffer teaches us how to best utilize mentors to carve our own path, how JOY in medicine lies in the JOurneY not necessarily the outcomes, and the ephemeral nature of success, which is why “you can't enjoy the successes too much or wallow in the failures too much because they're going to flip around.” Pearls of Wisdom:   1. We have to remember history in order to define the present and improve the future. The greatest memory tool is talking to the patient, asking the patient, and letting that serve as the way we remember their story. 2. Don't connect failure or success to the end result; focus on improving the journey and finding joy in that process. 3. You don't have to be a mentor's shadow; talk about your path and vision with them to gain insight on how you can achieve that. 4. Have fun everyday and never miss a meal.

Commentary by Dr. Yoshihiro Inamoto

The Osteosarcoma Institute (OSI) is currently supporting two clinical trials and seven laboratory research projects for osteosarcoma. In this OsteoBites episode, you will meet Lee J. Helman, MD, Director of the OSI and Chand Khanna, DVM, PhD, Chair of the OSI's Strategic Advisory Board. Dr. Helman and Dr. Khanna will provide an overview of the OSI's osteosarcoma research portfolio and explain how the OSI identifies promising osteosarcoma research projects. Lee J. Helman, MD has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. Dr. Helman completed his post-doctoral training at the National Cancer Institute (NCI). He then became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI, in 1993. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and served as Scientific Director for Clinical Research in the Center for Cancer Research, National Cancer Institute from 2007 to 2016. He joined Children's Hospital Los Angeles (CHLA) and the University of Southern California (USC) in 2017 as the Section Head of Basic and Translational Research within the Cancer and Blood Disease Institute (CBDI) and the Division of Hematology, Oncology and Blood and Marrow Transplantation. He remains an adjunct professor at CHLA. He has also trained many investigators in the field of pediatric sarcomas over the course of his career. He is currently focusing on improving outcomes in osteosarcoma as the Director of the Osteosarcoma Institute. Chand Khanna, DVM, PhD is Chief Science Officer with Ethos Veterinary Health, and President of Ethos Discovery(501c3), its incubator of scientific innovation. His responsibility at Ethos Discovery is to develop innovations in the form of novel diagnostics and therapeutics for both human and animal patients afflicted with similar complex disease conditions (i.e., osteosarcoma; so called Comparative Oncology). Dr. Khanna is a veterinary oncologist and both osteosarcoma and metastasis biologist, who has worked in this scientific field for over 20 years, most notably as a senior investigator of the Tumor and Metastasis Biology section of the Pediatric Oncology Branch at the National Cancer Institute and founding Director of its Comparative Oncology Program. Dr. Khanna's research career has focused on improving the understanding of the biology of metastasis in osteosarcoma and the use of a cross species (mouse, dog, human), Comparative and translational approach to develop novel therapeutics for osteosarcoma metastasis. He serves as the Chair of the Osteosarcoma Institute's Strategic Advisory Board. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

In this episode, Frederick Appelbaum, executive vice president, professor in the Clinical Research Division, and Metcalfe Family/Frederick Appelbaum Endowed Chair in Cancer Research at Fred Hutchinson Cancer Center, speaks with Alexandria Carolan, associate editor with the Cancer History Project. Delving deep into Thomas's role in discovering bone marrow transplantation and its role in curing hematologic cancers, Appelbaum, who became Thomas's mentee and collaborator, wrote “Living Medicine: Don Thomas, Marrow Transplantation, and the Cell Therapy Revolution.” “If it hadn't been told, and if the story had been lost to history, I just thought that would be a tragedy,” Appelbaum said to The Cancer Letter. “We've gone from a setting where Don and just one or two other people were the only ones that thought marrow transplantation was even possible in the 1950s, to today, where there are 100,000 transplants performed worldwide every year and 40 million people have signed up and registered to be potential stem cell donors.” A transcript of this recording appears on the Cancer History Project.

OSI Connect is the Osteosarcoma Institute's free, easy-to-use resource for patients who have been diagnosed with osteosarcoma or suffered a relapse after initial treatment. In this OsteoBites episode, you will meet Lee J. Helman, MD, Director of the OSI and Chelsey Blanks, OSI Connect Administrator. You will learn how OSI Connect works and examples of how the program has helped more than 70 patients since its launch in 2019. Lee J. Helman, MD has been studying the biology and caring for pediatric patients with sarcomas for over thirty years. Dr. Helman completed his post-doctoral training at the National Cancer Institute (NCI). He then became Head of the Molecular Oncology Section, Pediatric Oncology Branch, NCI, in 1993. He served as Chief of the Pediatric Oncology Branch from 1997-2007 and served as Scientific Director for Clinical Research in the Center for Cancer Research, National Cancer Institute from 2007 to 2016. He joined Children's Hospital Los Angeles (CHLA) and the University of Southern California (USC) in 2017 as the Section Head of Basic and Translational Research within the Cancer and Blood Disease Institute (CBDI) and the Division of Hematology, Oncology and Blood and Marrow Transplantation. He remains an adjunct professor at CHLA. He has also trained many investigators in the field of pediatric sarcomas over the course of his career. He is currently focusing on improving outcomes in osteosarcoma as the Director of the Osteosarcoma Institute. As the Osteosarcoma Institute Operations Manager, Chelsey Blanks schedules meetings for the board, oversees various operational aspects of the organization (including HR, IT, and office management), facilitates the grant cycle, and manages OSI Connect (formerly OSI Hotline) that offers free expert advice for osteosarcoma patients and families no matter where they are in their journey. Although Chelsey is Texan through and through, she spent six years living in Southern California and was thrilled to return to the homeland with her husband, Jordan, at the end of 2019. Chelsey obtained her undergraduate degree from the University of North Texas, where she studied Sociology, Philosophy, and Dance. Previously, she had an insurance and financial services career and was an Executive Assistant for her church in Orange County, California. --- What We Do at MIB Agents: PROGRAMS: End-of-Life MISSIONS Gamer Agents Agent Writers Prayer Agents Healing Hearts - Bereaved Parent and Sibling Support Ambassador Agents - Peer Support Warrior Mail Young Adult Survivorship Support Group EDUCATION for physicians, researchers and families: OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma MIB Book: Osteosarcoma: From our Families to Yours RESEARCH: Annual MIB FACTOR Research Conference Funding multiple $100,000 and $50,000 grants annually for OS research MIB Testing & Research Directory The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. https://www.mibagents.org​ Help support MIB Agents, Donate here https://give-usa.keela.co/embed/YAipuSaWxHPJP7RCJ SUBSCRIBE for all the Osteosarcoma Intel

Dr. Richard K. Burt MD ( https://astemcelljourney.com/about/drrichardburt/ ) is a Fulbright Scholar, Professor of Medicine at Scripps Health Care, tenured retired Professor of Medicine at Northwestern University where he served as Chief of Immunotherapy and Autoimmune Diseases, and CEO of Genani Biotechnology. Dr. Burt endeavored for thirty-five years, first with animal models and then with some of the world's first clinical trials, to bring the field of stem cell and cellular therapy to the patient's bedside. Dr. Burt has published more than 145 mostly first author articles and is the Editor of four medical textbooks. He was the first Autoimmune Committee Chairperson for the International Bone Marrow Transplant Registry (IBMTR) and was the principal investigator of a National Institute of Health (NIH) $10,000,000 multi-center contract to develop stem cell clinical trials for autoimmune diseases. Dr. Burt performed America's first hematopoietic stem cell transplant (HSCT) for multiple sclerosis (MS), systemic lupus erythematosus (SLE), Crohn's disease (CD), stiff person syndrome (SPS), and chronic inflammatory demyelinating polyneuropathy (CIDP) and published the world's first randomized clinical stem cell transplantation trials for systemic sclerosis and multiple sclerosis. Dr. Burt has been awarded Leukemia Scholar of America, the Lupus Foundation of America Fidelitas Award, the Van Bekkum Award by the European Society for Blood and Marrow Transplantation, the Distinguished Clinical Achievement Award by the Clinical Research Forum, and the European Group for Blood and Marrow Transplantation Clinical Achievement Award. Dr. Burt was presented in Vatican City, Rome with the “Keys to the Vatican”, was speaker at the Festival of Thinkers in Leadership in Healthcare in the United Arab Emirates, and chaired the biotechnology session at the Baku Azerbaijan International Humanitarian Forum. Dr. Burt was recognized by Science Illustrated for accomplishing one of the Top 10 medical breakthroughs for the next ten years, and by Scientific American as one of the Top 50 individuals, teams, or organizations for improving humanity and outstanding leadership. His newest book is entitled "Everyday Miracles - Curing Multiple Sclerosis, Scleroderma, and Autoimmune Diseases by Hematopoietic Stem Cell Transplant". Support the show

Prof. Dr. Sven Meuth erklärt für wen und zu welchem Zeitpunkt der Multiplen Sklerose die Stammzelltransplantation / HSCT / aHSCT Sinn macht. Hier geht es zum Blogbeitrag, wo es den Beitrag auch zum Nachlesen gibt: https://ms-perspektive.de/prof-meuth-grundlagen-der-hsct Für Folge 174 habe ich mir Univ-Prof. Dr. Dr. Sven G. Meuth als Interviewgast eingeladen. Er ist Direktor der Klinik für Neurologie am Universitätsklinikum Düsseldorf. Seine Klinik gehört zu den wenigen in Deutschland, die eine autologe hämatopoetische Stammzelltransplantation, kurz HSCT bzw. aHSCT, für MS-Patienten anbieten. Doch während manche die Stammzelltransplantation (HSCT) als heiligen Gral ansehen, macht dieser therapeutische Ansatz nur für eine bestimmte Zielgruppe innerhalb der Menschen mit MS Sinn. Wir sprechen über die Grundlagen und vor allem für wen und innerhalb welchen Zeitfensters die Behandlung eine sinnvolle Option ist. Inhaltsverzeichnis Vorstellung Grundlagen der krankhaften Veränderungen bei MS Autologe hämatopoetischen Stammzelltransplantation kurz aHSCT, auch HSCT Blitzlicht-Runde Verabschiedung Wo findet man mehr Informationen zum Thema autologe Stammzelltransplantation? Die European Society for Blood and Marrow Transplantation, die Deutsche Multiple Sklerose Gesellschaft und die Deutsche Gesellschaft für Neurologie sowie das Kompetenznetz Multiple Sklerose haben einige hilfreiche Online-Ressourcen darüber veröffentlicht. Welche Entwicklung für die autologe Stammzelltransplantation bei MS wünschen sie sich in den kommenden 5 Jahren? Auf jeden Fall einige hochwertige, multizentrische, randomisierte, kontrollierte klinische Studien. Diese bilden die Grundlage für bewährte medizinische Verfahren. Verabschiedung Möchten sie den Hörerinnen und Hörern noch etwas mit auf dem Weg geben? Ich bedanke mich herzlich für Ihr Interesse und wünsche allen Zuhörer:Innen alles Gute! Um Updates zur MS, der Arbeit in unserer Klinik und Neuigkeiten aus der Forschung zu erhalten vernetzen Sie sich mit uns auf Instagram unter  (@reinenervensache_meuth)  oder schauen Sie auf unseren Blog: www.reine-nervensache.de.   Vielen Dank an Prof. Dr. Sven Meuth für die Ausführung zur Stammzelltransplantation und der Erläuterung, für welche Patienten sie Sinn macht und wann und welche Risikoabwägungen getroffen werden müssen. Bis bald und mach das Beste aus Deinem Leben, Nele Mehr Informationen und positive Gedanken erhältst Du in meinem kostenlosen Newsletter. Hier findest Du eine Übersicht zu allen bisherigen Podcastfolgen.

Skid Row is back for the attack with their brand new lead singer Erik Grönwall. On this episode of Kasarin Lapset aka. The Children Of The Eighties we have Erik as a guest so listen how did Erik end up working with legendary band and how has his ride been with Skid Row so far. Erik will also tell us how did the recording of the forthcoming Skid Row work and he'll also give us an update on his healthy issues. Kasarin Lapset -podcast is hosted by Vesa Winberg. * * * Kasarin Lapset -podcast is roasted together with the best roastery in Finland - www.lehmusroastery.com * * * Use the code "rocknrollneverdies" and get 15% discount on your coffee-, tea- or cocoa purchases from Lehmus Roastery website. * * * Kasarin Lapset Rocks With Skipper's Amps - No compromises, no nonsense, just gear to rock * * * Kasarin Lapset -theme: Niko "Richie" Kudjoi Kasarin Lapset -voice: Panu Markkanen Kasarin Lapset -photo: Kristian Valkama * * * Production: SoundWorks Finland * * * www.soundworksfinland.fi

Rabi Hanna, MD, Chair of the Department of Pediatric Hematology, Oncology and Blood and Marrow Transplantation at Cleveland Clinic Children's joins the Cancer Advances podcast to discuss the use of gene therapy in sickle cell disease. Listen as Dr. Hanna describes how the last several years have brought significant advancements in the field, expanding our understanding and treatment of sickle cell disease, including the possibility of curative gene therapy.

Rabi Hanna, MD, Chair of the Department of Pediatric Hematology, Oncology and Blood and Marrow Transplantation at Cleveland Clinic Children's and Angelika Erwin, MD, PhD, Medical Geneticist at the Center for Personalized Genetic Healthcare at the Cleveland Clinic join the Cancer Advances podcast to discuss the lysosomal storage disease program (LSD). Listen as Dr. Hanna and Dr. Erwin discuss how the interdisciplinary team for children and adults with LSDs is dedicated to improving diagnosis, management and treatment of these disorders.

Dr Ross has a Ph.D. in Immunology from the Professor Robert Levy Laboratory at the University of Miami, with preliminary work in Biochemistry and Molecular Biology.   We find out how exosomes impact us, the cutting edge science behind them and how they are use. We unpack the controversy around treatments and use of exosomes, and so much more.   He has published in Blood and the Biology of Blood and Marrow Transplantation as well as Protein Expression and Purification, Dr. Ross' current focus is developing cell free exosome-based therapies via Kimera Labs Inc.   Kimera Labs produces sterile amniotic fluid filtered exosomes and its flagship patent pending XoGlo product which is, a pharmaceutical grade isolated Placental MSC exosome re-suspended in saline with applications including wound healing, as well as a current COVID-19 filing with the FDA.   Dr. Ross has concentrated on the development of a quality driven 27,000 sq ft cGMP facility in Miami Florida, staffed by 40 Floridians and dedicated to the production of exosome candidates for the treatment of human disease.     ORDER YOUR ADDITIVE FREE, ORGANIC, KETO FRIENDLY WINES HERE With your Initial Order Get a Bottle For 1 PENNY- www.oldguytalks.com/dryfarms   Find The Old Guy Here   Website: https://www.oldguytalks.com/ Facebook: https://www.facebook.com/orest.kman https://www.facebook.com/oldguytalks Instagram: https://www.instagram.com/oldguytalks/ Twitter: https://twitter.com/oldguytalks Youtube: https://www.youtube.com/results?search_query=orest+k-man LinkedIn: https://www.linkedin.com/in/orestkomarnyckyj/   #prostate cancer #prostatectomy #ed #erectiledysfunction #depends # #urinaryincontinence #oldschool #guy #men #dude #male #gentleman #masculinity #masculine #manhood #antiaging #gentlemanmodern #gentlemanlife #gentlemanrules #gentlemanguide #podcasterthoughts #podcastersoninstagram #podcasterslife #podcastlife #relationshippodcast #fitnessworldwide #podcastersofig #podcastersunite #podcastersofcolor #sexpodcast #babyboomerstyle #fitnesspodcast #agingwell #podcasthost #podcastlove #podcastshow #sixfigures #sixfigureincome #betterlifestyle 

Each September, Children's of Alabama honors Childhood Cancer and Sickle Cell Awareness Month. This two-part, Inside Pediatrics Podcast series features two physicians from the UAB Division of Pediatric Hematology, Oncology and Blood and Marrow Transplantation. In episode one, Dr. Matthew Kutny, director of the Leukemia, Lymphoma and Histiocytosis (LLH) Program, reveals how the new generation of treatments is more customized for each patient and targeted for each type of cancer.

In this episode of The Moss Report Podcast, Ralph W. Moss, PhD speaks with Dipnarine Maharaj, MD, about his Florida-based clinic and his latest research. An expert in immunology, Dr. Maharaj has conducted research on stem cell therapies for cancer, blood disorders, and diseases associated with aging. He has developed clinical protocols for the treatment of autoimmune disorders, cardiac diseases, strokes, Parkinson's disease, and Alzheimer' disease. He aims to educate the public on stem cells and their immune regenerative capabilities through his Advanced Stem Cell Education Program (ASTEP). Dr. Maharaj obtained his medical degree from the University of Glasgow Medical School, Scotland. He is the Founder and Medical Director of the South Florida Bone Marrow Stem Cell Transplant Institute, The Maharaj Institute of Immune Regenerative Medicine, and The Stem Cell Cryobank.  He has had numerous publications in Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation, British Medical Journal, British Journal of Hematology and Lancet. To learn more about his current research and institutional endeavors, visit the Maharaj Institute website here.